30.06.2025

Alithea Bio at #BayOConnect2025: Let’s Shape the Future of Immunotherapy

bayoconnect 2025 AlitheaBio

We’re excited to announce that Alithea Bio will be attending #BayOConnect2025 in Munich on 1–2 July 2025.

We’re excited to announce that Alithea Bio will be attending BayOConnect in Munich on 1–2 July 2025.

Our Chief Scientific Officer, Dr. Tim Fugmann, will be taking the stage on 2 July 2025, between 11:30 AM and 12:30 PM, to share insights into our cutting-edge work in immunotherapy.

📍 Schedule a meeting with us to discuss

  • Navigating peptide presentation with HLA-Compass

  • Discovering and validating target (neo)epitopes

  • Predicting off-target toxicity

  • Exploring our HLA-typed biorepository

If you’re attending the conference, we’d love to connect and explore how Alithea Bio can support your goals in immunotherapy, cancer research, and HLA-peptidomics.

Let’s shape the future of precision medicine together.

Read more

neoantigen discovery 202

The Future of Neoantigen Discovery: Trends and Challenges

Read
off-target toxicity prediction

Off-Target Toxicity in Immunotherapy: Identification and Mitigation Strategies

Read
mass spectrometry HLA peptide analysis

Mass Spectrometry vs. NGS for HLA Peptide Analysis:Pros and Cons

Read